Isoniazid‐Dihydropyrimidinone Molecular Hybrids: Design, Synthesis, Antitubercular Activity, and Cytotoxicity Investigations with Computational Validation
Authors:
- 1 April 2025
- journal article
- Published by Wiley in ChemMedChem
- Vol. 20 (11) , e202400949
Abstract
A new series of isoniazid‐dihydropyrimidinone molecular hybrids (8a–8n) were designed, synthesized and structurally characterized using different spectroscopic techniques viz., Fourier transform infrared spectroscopy, nuclear magnetic resonance (NMR), and high‐resolution mass spectrometry followed by their antitubercular evaluation including their precursors (4a–4n), and a standard antitubercular drug (isoniazid; INH). The molecular hybrids particularly 8g (minimum inhibitory concentration (MIC) = 6.25 μg mL−1), 8h (MIC = 1.56 μg mL−1), 8k (MIC = 0.78 μg mL−1), 8l (MIC = 6.25 μg mL−1), and 8n (MIC = 0.39 μg mL−1) demonstrated the most potent inhibitory activity against wild‐type M. tuberculosis mc26230, disclosing 8n as the most potent compound in the series. However, the potent compounds lost their activity against three INH‐resistant M. tuberculosis strains mutated in katG. The more efficient compounds (8h, 8k, and 8n) were subsequently evaluated for their cytotoxicity against the THP‐1 human monocytic cell line. Furthermore, the stability studies of the most potent compound carried out using 1H NMR, UV‐visible, and liquid chromatography‐mass spectrometry revealed their structural integrity. Finally, in silico molecular docking simulations were conducted to explore the binding orientations of the potent compounds in the active site of the target protein InhA while ADME/T (absorption, distribution, metabolism, excretion, and toxicity) and global reactivity parameters were explored to determine their drug‐likeness and stability profiles, respectively.Keywords
Funding Information
- Association Vaincre la Mucoviscidose (RF20230503223)
- Fondation pour la Recherche Médicale (Equipe FRM EQU202103012588)
This publication has 50 references indexed in Scilit:
- Design, Synthesis, and Anti‐Mycobacterial Evaluation of Triclosan‐Isoniazid HybridsChemistry & Biodiversity, 2024
- Isoniazid Hybrids As Potential Antitubercular AgentsChemistrySelect, 2024
- Synthesis, antimicrobial evaluation, and in silico studies of quinoline—1H-1,2,3-triazole molecular hybridsMolecular Diversity, 2020
- DFT calculations on molecular structures, HOMO–LUMO study, reactivity descriptors and spectral analyses of newly synthesized diorganotin(IV) 2‐chloridophenylacetohydroxamate complexesJournal of Computational Chemistry, 2019
- Design, synthesis and pharmacological evaluation of some substituted dihydropyrimidines with L-/T-type calcium channel blocking activitiesBioorganic Chemistry, 2019
- N-Acylhydrazones as drugsBioorganic & Medicinal Chemistry Letters, 2018
- Molecular Hybridization Tools in the Development of Furoxan‐Based NO‐Donor ProdrugsChemMedChem, 2017
- Synthesis and biological evaluation of novel N3- substituted dihydropyrimidine derivatives as T-type calcium channel blockers and their efficacy as analgesics in mouse models of inflammatory painBioorganic & Medicinal Chemistry, 2017
- Synthesis and evaluation of dihydropyrimidinone-derived selenoesters as multi-targeted directed compounds against Alzheimer’s diseaseBioorganic & Medicinal Chemistry, 2016
- N‐Benzyl‐4‐((heteroaryl)methyl)benzamides: A New Class of Direct NADH‐Dependent 2‐trans Enoyl–Acyl Carrier Protein Reductase (InhA) Inhibitors with Antitubercular ActivityChemMedChem, 2016